Antiphospholipid antibody mechanisms of thrombosis

Pier Luigi Meroni, Chiara Crotti, Cecilia Chighizola

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-phospholipid antibodies (aPL) are diagnostic and pathogenic antibodies. There is evidence from both in vitro and in vivo models that they can mediate thrombosis through several mechanisms. aPL may interact with beatta-2 glycoprotein I or with prothrombin and may interfere with fluid- phase coagulation steps: inhibition of protein C-S activity and fibrinolysis. More importantly beta-2 glycoprotein I –dependent aPL may recognize their own target on several cell types involved in the coagulation: endothelial cells, peripheral blood monocytes, and platelets. Once bound aPL may induce a pro-inflammatory and pro-coagulant endothelial phenotype, may induce tissue factor expression on monocytes, and can increase aggregation of platelets stimulated by another agonist. All these mechanisms may play a role in supporting the thrombophilic state of the anti-phospholipid syndrome. aPL are necessary for clotting but are not sufficient and require an additional stimulus (two- hit theory) and complement activation so explaining why thrombosis can occur only sometimes in spite of the persistent presence of the antibodies.

Original languageEnglish
Title of host publicationAntiphospholipid Antibody Syndrome: From Bench to Bedside
PublisherSpringer International Publishing
Pages25-35
Number of pages11
ISBN (Print)9783319110448, 9783319110431
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Antiphospholipid Antibodies
Anti-Idiotypic Antibodies
Phospholipids
Thrombosis
Monocytes
beta 2-Glycoprotein I
Coagulants
Antiphospholipid Syndrome
Antibodies
Complement Activation
Protein S
Thromboplastin
Prothrombin
Fibrinolysis
Protein C
Platelet Aggregation
Glycoproteins
Blood Platelets
Endothelial Cells
Phenotype

Keywords

  • Beta-2 glycoprotein I
  • Endothelial cell
  • Monocytes
  • Pathogenesis
  • Platelets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Meroni, P. L., Crotti, C., & Chighizola, C. (2015). Antiphospholipid antibody mechanisms of thrombosis. In Antiphospholipid Antibody Syndrome: From Bench to Bedside (pp. 25-35). Springer International Publishing. https://doi.org/10.1007/978-3-319-11044-8_3

Antiphospholipid antibody mechanisms of thrombosis. / Meroni, Pier Luigi; Crotti, Chiara; Chighizola, Cecilia.

Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, 2015. p. 25-35.

Research output: Chapter in Book/Report/Conference proceedingChapter

Meroni, PL, Crotti, C & Chighizola, C 2015, Antiphospholipid antibody mechanisms of thrombosis. in Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, pp. 25-35. https://doi.org/10.1007/978-3-319-11044-8_3
Meroni PL, Crotti C, Chighizola C. Antiphospholipid antibody mechanisms of thrombosis. In Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing. 2015. p. 25-35 https://doi.org/10.1007/978-3-319-11044-8_3
Meroni, Pier Luigi ; Crotti, Chiara ; Chighizola, Cecilia. / Antiphospholipid antibody mechanisms of thrombosis. Antiphospholipid Antibody Syndrome: From Bench to Bedside. Springer International Publishing, 2015. pp. 25-35
@inbook{474323b94be0447bb1cc0bca4e8223fa,
title = "Antiphospholipid antibody mechanisms of thrombosis",
abstract = "Anti-phospholipid antibodies (aPL) are diagnostic and pathogenic antibodies. There is evidence from both in vitro and in vivo models that they can mediate thrombosis through several mechanisms. aPL may interact with beatta-2 glycoprotein I or with prothrombin and may interfere with fluid- phase coagulation steps: inhibition of protein C-S activity and fibrinolysis. More importantly beta-2 glycoprotein I –dependent aPL may recognize their own target on several cell types involved in the coagulation: endothelial cells, peripheral blood monocytes, and platelets. Once bound aPL may induce a pro-inflammatory and pro-coagulant endothelial phenotype, may induce tissue factor expression on monocytes, and can increase aggregation of platelets stimulated by another agonist. All these mechanisms may play a role in supporting the thrombophilic state of the anti-phospholipid syndrome. aPL are necessary for clotting but are not sufficient and require an additional stimulus (two- hit theory) and complement activation so explaining why thrombosis can occur only sometimes in spite of the persistent presence of the antibodies.",
keywords = "Beta-2 glycoprotein I, Endothelial cell, Monocytes, Pathogenesis, Platelets",
author = "Meroni, {Pier Luigi} and Chiara Crotti and Cecilia Chighizola",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-11044-8_3",
language = "English",
isbn = "9783319110448",
pages = "25--35",
booktitle = "Antiphospholipid Antibody Syndrome: From Bench to Bedside",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Antiphospholipid antibody mechanisms of thrombosis

AU - Meroni, Pier Luigi

AU - Crotti, Chiara

AU - Chighizola, Cecilia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Anti-phospholipid antibodies (aPL) are diagnostic and pathogenic antibodies. There is evidence from both in vitro and in vivo models that they can mediate thrombosis through several mechanisms. aPL may interact with beatta-2 glycoprotein I or with prothrombin and may interfere with fluid- phase coagulation steps: inhibition of protein C-S activity and fibrinolysis. More importantly beta-2 glycoprotein I –dependent aPL may recognize their own target on several cell types involved in the coagulation: endothelial cells, peripheral blood monocytes, and platelets. Once bound aPL may induce a pro-inflammatory and pro-coagulant endothelial phenotype, may induce tissue factor expression on monocytes, and can increase aggregation of platelets stimulated by another agonist. All these mechanisms may play a role in supporting the thrombophilic state of the anti-phospholipid syndrome. aPL are necessary for clotting but are not sufficient and require an additional stimulus (two- hit theory) and complement activation so explaining why thrombosis can occur only sometimes in spite of the persistent presence of the antibodies.

AB - Anti-phospholipid antibodies (aPL) are diagnostic and pathogenic antibodies. There is evidence from both in vitro and in vivo models that they can mediate thrombosis through several mechanisms. aPL may interact with beatta-2 glycoprotein I or with prothrombin and may interfere with fluid- phase coagulation steps: inhibition of protein C-S activity and fibrinolysis. More importantly beta-2 glycoprotein I –dependent aPL may recognize their own target on several cell types involved in the coagulation: endothelial cells, peripheral blood monocytes, and platelets. Once bound aPL may induce a pro-inflammatory and pro-coagulant endothelial phenotype, may induce tissue factor expression on monocytes, and can increase aggregation of platelets stimulated by another agonist. All these mechanisms may play a role in supporting the thrombophilic state of the anti-phospholipid syndrome. aPL are necessary for clotting but are not sufficient and require an additional stimulus (two- hit theory) and complement activation so explaining why thrombosis can occur only sometimes in spite of the persistent presence of the antibodies.

KW - Beta-2 glycoprotein I

KW - Endothelial cell

KW - Monocytes

KW - Pathogenesis

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84944543851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944543851&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-11044-8_3

DO - 10.1007/978-3-319-11044-8_3

M3 - Chapter

SN - 9783319110448

SN - 9783319110431

SP - 25

EP - 35

BT - Antiphospholipid Antibody Syndrome: From Bench to Bedside

PB - Springer International Publishing

ER -